Trevena Past Earnings Performance
Past criteria checks 0/6
Trevena's earnings have been declining at an average annual rate of -11%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 3.9% per year.
Key information
-11.0%
Earnings growth rate
11.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 3.9% |
Return on equity | n/a |
Net Margin | -8,358.2% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Trevena Q2 2022 Earnings Preview
Aug 10Trevena slides on $2M preferred stock offering
Jul 29Trevena (NASDAQ:TRVN) Will Have To Spend Its Cash Wisely
Jul 08Is Trevena (NASDAQ:TRVN) In A Good Position To Deliver On Growth Plans?
Mar 19Trevena Offers An Enticing Risk-Reward At These Prices
Dec 14Trevena: Remaining Patient After A Disappointing Q2 Earnings
Aug 17Trevena announces resumption of NIH-run trial for TRV734 in opioid use disorder
Jun 16Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles
May 10Trevena Investor Presentation - Slideshow
May 08Trevena (TRVN) Investor Presentation - Slideshow
Nov 16Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling
Nov 09DEA classifies Trevena's oliceridine, distribution to start in November
Oct 30Revenue & Expenses Breakdown
How Trevena makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -37 | 19 | 16 |
31 Mar 24 | 3 | -40 | 20 | 16 |
31 Dec 23 | 3 | -40 | 20 | 16 |
30 Sep 23 | 3 | -31 | 22 | 16 |
30 Jun 23 | 3 | -38 | 25 | 17 |
31 Mar 23 | 0 | -45 | 30 | 17 |
31 Dec 22 | 0 | -54 | 35 | 18 |
30 Sep 22 | 0 | -61 | 39 | 19 |
30 Jun 22 | 0 | -59 | 42 | 17 |
31 Mar 22 | 0 | -58 | 42 | 16 |
31 Dec 21 | 1 | -52 | 38 | 13 |
30 Sep 21 | 1 | -50 | 37 | 13 |
30 Jun 21 | 3 | -41 | 30 | 14 |
31 Mar 21 | 3 | -33 | 23 | 14 |
31 Dec 20 | 3 | -29 | 19 | 13 |
30 Sep 20 | 3 | -24 | 15 | 12 |
30 Jun 20 | 0 | -27 | 14 | 14 |
31 Mar 20 | 0 | -25 | 14 | 13 |
31 Dec 19 | 0 | -25 | 13 | 13 |
30 Sep 19 | 0 | -26 | 13 | 13 |
30 Jun 19 | 3 | -22 | 14 | 11 |
31 Mar 19 | 6 | -27 | 17 | 13 |
31 Dec 18 | 6 | -31 | 19 | 16 |
30 Sep 18 | 6 | -38 | 21 | 20 |
30 Jun 18 | 3 | -49 | 22 | 59 |
31 Mar 18 | 0 | -60 | 20 | 54 |
31 Dec 17 | 0 | -72 | 20 | 49 |
30 Sep 17 | 0 | -93 | 19 | 42 |
30 Jun 17 | 0 | -107 | 18 | 0 |
31 Mar 17 | 2 | -106 | 17 | 0 |
31 Dec 16 | 4 | -103 | 16 | 90 |
30 Sep 16 | 6 | -82 | 16 | 0 |
30 Jun 16 | 8 | -63 | 14 | 0 |
31 Mar 16 | 8 | -55 | 14 | 0 |
31 Dec 15 | 6 | -51 | 13 | 0 |
30 Sep 15 | 4 | -48 | 11 | 0 |
30 Jun 15 | 3 | -53 | 11 | 0 |
31 Mar 15 | 1 | -53 | 10 | 0 |
31 Dec 14 | 0 | -50 | 9 | 0 |
30 Sep 14 | 0 | -43 | 9 | 0 |
30 Jun 14 | 0 | -37 | 8 | 0 |
31 Mar 14 | 0 | -30 | 6 | 0 |
31 Dec 13 | 0 | -24 | 5 | 0 |
Quality Earnings: TRVN is currently unprofitable.
Growing Profit Margin: TRVN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRVN is unprofitable, and losses have increased over the past 5 years at a rate of 11% per year.
Accelerating Growth: Unable to compare TRVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: TRVN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.